NCT00531999 - Raltegravir Insulin Sensitivity Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

HIV Infections

Interventions

DRUG

Raltegravir then lopinavir/ritonavir

raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study

DRUG

Lopinavir/ritonavir then raltegravir

lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study

Trial Locations (1)

St Stephens Centre, Chelsea & Westminster Hospital, London

All Listed Sponsors

lead

St Stephens Aids Trust

OTHER